FEXIFLOW – 120

FEXIFLOW – 120 by Floriwa Labs (Division of Noxxon Pharmaceuticals Pvt. Ltd.) is a highly effective anti-allergic medication formulated with Fexofenadine Hydrochloride 120 mg. It belongs to the second-generation antihistamine class and is widely prescribed for the management of seasonal allergic rhinitis and other allergic conditions.

Fexofenadine works by blocking histamine (H1 receptors), a substance in the body responsible for allergic symptoms. FEXIFLOW – 120 provides fast and long-lasting relief from allergy symptoms without causing significant drowsiness, making it suitable for daily use.

Manufactured under strict quality standards, FEXIFLOW – 120 ensures high efficacy, safety, and patient compliance. It is trusted by healthcare professionals for reliable allergy management.

Indications

FEXIFLOW – 120 is indicated for:

• Seasonal allergic rhinitis

• Sneezing and runny nose

• Itchy or watery eyes

• Nasal congestion

• Urticaria (hives)

• Skin allergies

Uses

• Provides relief from common allergy symptoms

• Controls itching and skin rashes

• Reduces nasal and eye irritation

• Non-sedative antihistamine suitable for daytime use

• Helps improve overall quality of life during allergy seasons

Key Benefits

• 24-hour long-lasting relief

• Non-drowsy formula

• Rapid onset of action

• Well-tolerated and clinically proven molecule

• Quality assurance from Floriwa Labs

Dosage & Administration

The recommended dosage of FEXIFLOW – 120 is one tablet daily or as directed by a registered medical practitioner. The tablet should be swallowed whole with water and can be taken with or without food. Avoid taking with fruit juices as they may reduce absorption.

Precautions

• Use under medical supervision

• Not recommended for self-medication

• Inform the doctor in case of kidney problems

• Keep out of reach of children

FEXIFLOW – 120 by Floriwa Labs (Division of Noxxon Pharmaceuticals Pvt. Ltd.) is a trusted and effective solution for allergy relief, ensuring comfort, safety, and improved patient outcomes.